IUSM scientists lead $12 million national research initiative for inherited cancers

September 3, 2015

The Indiana University School of Medicine has been selected to lead a five-year, $12 million national research project to develop new treatments for diseases of a genetic mutation that leads to disfiguring and life-threatening tumors and other developmental disorders, mainly in children. The grant, one of the highly competitive and coveted projects funded by the National Cancer Institute's Specialized Programs of Research Excellence initiative, is the first such SPORE grant to focus on pediatric cancers.

D. Wade Clapp, M.D., is chairman of IUSM Department of Pediatrics | Photo By TIM YATES

"This grant enables us to engage in research from the basic science lab to clinical trials to discover new treatments for a broad range of devastating cancers and related disorders, drawing on a team of some of the finest researchers in this field across the country," said D. Wade Clapp, M.D., chairman of the Department of Pediatrics at the IU School of Medicine and a member of both the IU Melvin and Bren Simon Cancer Center and the Herman B Wells Center for Pediatric Research.

Dr. Clapp, who will serve as the corresponding principal investigator for the new project, said the funding will enable researchers to determine the complete genetic sequence of the research participants, providing unique opportunities to design precise treatments for patients, to adopt new research techniques and better understand how tumors develop resistance to drugs.

Learn more about this research initiative and the SPORE grants on the IUSM newsroom.